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Abstract
Avian H5N1 influenza viruses cause severe disease and high mortality in infected humans. However, tissue tropism and
underlying pathogenesis of H5N1 virus infection in humans needs further investigation. The objective of this work was to
study viremia, tissue tropism and disease pathogenesis of H5N1 virus infection in the susceptible ferret animal model. To
evaluate the relationship of morbidity and mortality with virus loads, we performed studies in ferrets infected with the H5N1
strain A/VN/1203/04 to assess clinical signs after infection and virus load in lung, brain, ileum, nasal turbinate, nasal wash,
and blood. We observed that H5N1 infection in ferrets is characterized by high virus load in the brain and and low levels in
the ileum using real-time PCR. In addition, viral RNA was frequently detected in blood one or two days before death and
associated with symptoms of diarrhea. Our observations further substantiate pathogenicity of H5N1 and further indicate
that viremia may be a bio-marker for fatal outcomes in H5N1 infection.
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Introduction
In 1997, the avian influenza A virus subtype H5N1, which is a
highly pathogenic H5N1 avian influenza initially confined to
poultry, crossed the avian-human species barrier [1,2], and has
since emerged as a highly fatal infectious disease in the human
population. To date, the World Health Organization has reported
467 laboratory-confirmed cases, 282 of which were fatal, resulting in
a fatality rate of ,60% (World Health Organization http://www.
who.int/csr/disease/avian_influenza/country/cases_table_2009_12_
30/en/index.html). Although it is more than 10 years since human
H5N1 cases were reported, H5N1 influenza is poorly understood in
terms of its pathology and pathogenesis. Only a limited number of
reports describing pathological findings in human H5N1 cases have
been published. Nevertheless, recent studies combined with early
findings have gradually resulted in a better understanding of cell and
organ pathology caused by H5N1, as well as viral tissue tropism.
The primary pathologic process that causes death is fulminant
viral pneumonia [2]. High replication efficiency, broad tissue
tropism and systemic replication seem to determine the pathoge-
nicity of H5N1 viruses in animals [3]. The human isolate A/
Vietnam/1203/04 (H5N1) was reported to be highly pathogenic
and the severity of disease was associated with broad tissue tropism
and high virus titers in multiple organs, including the brain [4]. In
vitro and animal model studies indicate that high and disseminat-
ed viral replication is an important factor in disease pathogenesis
[4–7]. Ferrets are an excellent mammalian animal model for
studies of influenza virus pathogenicity and host immunity, and
disease manifestations of influenza virus infection in ferrets closely
resemble those in humans. To evaluate the relationship of
morbidity and mortality with virus loads, we performed studies
in ferrets infected with the H5N1 strain A/VN/1203/04 to assess
clinical signs after infection and virus load in lung, brain, ileum,
nasal turbinate, nasal wash, and blood.
Results
Disease Signs Caused by Human A/VN/1203/04
To evaluate virologic characteristics in susceptible ferrets, 24
ferrets (12/group) were challenged with either 1 FLD50 (50%
ferret lethal dose) or 10 FLD50 of the H5N1 strain A/VN/1203/
04 on Day 0, since these doses were known to cause symptomatic
infection to varying degrees in the susceptible animal models. All
ferrets were observed to be clinically normal on Day 0. Clinical
signs of infection were initially observed on Day 2 postinfection
with most animals exhibiting signs by Days 3 or 4 postinfection.
Clinical signs observed in both groups included diarrhea, nasal
discharge, hypoactivity and recumbency (Table 1). The number of
ferrets that demonstrated clinical symptoms in the group that
received the high dose (10 FLD50) of virus was higher than in the
group receiving 1 FLD50. Greater mortality was observed in the
high dose group, with three ferrets euthanized as scheduled two
found dead on Day 4 and the remaining seven at Day 10
postinfection. In the low dose group, four ferrets were euthanized
as scheduled on Day 4 postinfection, four ferrets were found dead
between Days 6 and 8 and four ferrets survived until sacrifice on
Day 11.
We examined all clinical symptoms during the course of
infection to characterize the disease caused by H5N1 infection and
to identify characteristics that explain the severity of infection. We
observed high fevers (39.3,41.5uC in the 10 FLD50 group and
38.3,41.3uC in the 1 FLD50 group) on Day 2 or Day 7
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during Day 2 and Day 9 postinfection in the 10 FLD50 group; 6%
by Day 4 postinfection in the 1 FLD50 group) (Fig. 1B). Diarrhea
was one of the most frequently observed clinical symptoms, as all
ferrets exhibited yellow diarrhea before death (Table 1).
There was a greater increase in weight loss and body
temperatures for longer duration in the 10 FLD50 group compared
to the 1 FLD50 group. In the latter group, ferrets regained body
weight after Day 7 and their body temperature returned to normal
after Day 8 post-infection, suggesting that some animals in this
group recovered from the disease. Not surprisingly, the virus dose
of 1 FLD50 was not sufficient to cause death in all ferrets, as the
majority remained alive on Day 11 post-infection, the day of
scheduled sacrifice. Using the FLD50 assay, we found that virus
could be detected in the nasal washes more frequently in animals
in the 10 FLD50 group compared with those in the 1 FLD50
group (Fig. 1C). Nasal wash samples had viral load detectable on
Days 2 in both groups, and increased levels were observed at Days
4 and 6 using FLD50 assay (Fig. 1C).
Virus Load in Organs
The severity of clinical signs and symptoms, including diarrhea,
induced by infection with H5N1 indicated a rapid spread of the
virus
4 confirmed by virus detection in multiple organs, including
the brain (Table 2), using the real-time PCR technique. There was
a clear trend toward detection of higher titers of virus in the brain
than in other organs, in both the 1 FLD50 and 10 FLD50 groups.
The titers of virus in the lung were slightly lower than in the brain.
Virus was also detected in the ileum (Table 2). These results
indicate that disease severity or fatality caused by the virus was
associated with broad issue tropism and high virus titers in
multiple organs, particularly the brain.
Association of Viremia with Death of Ferrets
It has been previously reported that virus could be detected in
blood in severely ill patients [5,6]. We wished to further examine
the relationship between viremia and fatal outcomes. To address
this issue, we extracted nucleic acids from the blood of infected
ferrets on Days 0, 1, 2, 4, and 6 postinfection with A/VN1203/04,
and performed real-time RT-PCR (Table 3). We found that there
was a clear tendency for virus to be detected in blood one or two
days before the animal died (during the Day 4 and Day 8 period
postinfection in the 10 FLD 50 group and between Day 5 and Day
6 postinfection in the 1 FLD50 group), with accompanying
symptoms of diarrhea, suggesting that viremia could potentially be
a predictable biomarker for animal death. We could not detect
virus in the blood of two ferrets that died after Day 8 postinfection
(the first on Day 9 postinfection, the second on Day 10
postinfection) of the 10 FLD 50 group, and two ferrets that died
after Day 7 postinfection (the first on Day 8 postinfection, the
second on Day 9 postinfection) in 1 FLD50 group. We also found
a similar tendency in mice infected with the A/VN/1203/04
(H5N1) virus (data not shown). These data indicate that high titers
of viremia are a strong predictor of death in the untreated host.
For some animals that died later in infection there was no
detectable viremia prior to death, under our experimental
conditions.
Discussion
H5N1 virus related influenza remains a relatively novel disease
with poorly understood pathology and pathogenesis, and only a
limited numberofreportsdescribingpathologicalfindingsinhuman
H5N1 cases have been published [6]. Some studies have shown that
H5N1 virus is found exclusively in the respiratory tract (mainly in
the lung) [9,10]. Other studies report the presence of H5N1 viruses
in many extrapulmonary organs, such as intestine, liver, and brain
[3–7]. Viral RNA has been detected in nasopharyngeal aspirates
ranging from 1 day up to 15 days after disease onset [11,12]. Viral
replication appears to be prolonged in H5N1 influenza because
viral loads when plotted against time did not show a clear decline in
a large group of H5N1 patients [6]. Various animal studies indicate
that aberrant production of proinflammatory cytokines and
chemokines may play an important role in the pathogenesis of
H5N1 influenza, which is consistent with abnormal regulation of
cytokines and chemokines, including hemophagocytotic activity,
that have been described in H5N1 autopsy cases [10,12–14]. In
many H5N1 patients elevated serum levels of proinflammatory
cytokines and chemokines have been detected [6,10,12]. Apoptosis
in alveolar cells and infiltrating leukocytes are prominent findings
[15]. Lymphocyte depletion occurs in the spleen, lymph nodes, and
tonsils; and reactive hemophagocytosis presumably result from host
cytokine responses and viral infection.
Thus far, several hundred human infections with avian H5N1
viruses have been confirmed. The A/VN/1203/04 strain that we
used in our study is a highly pathogenic isolate[4]. This viral strain
caused viremia and was lethal to ferrets (Table 1). Viral sequences
and antigens have been detected in lymphocytes in lymph node
tissue, as well as in Hofbauer cells (macrophages of the placenta),
Kupffer cells (macrophages of the liver), and mononuclear cells in the
intestinal mucosa [15,16]. Recently, it has been reported that viral
RNA was found in the blood of humans with fatal outcomes while no
viral RNA could be detected in the blood of surviving H5N1-infected
individuals [6]. This is consistent with the findings we report here in
ferrets. Accordingly, extra-pulmonary dissemination may be the
result of viremia or of infected immune cells transporting virus to
other organs, although this remains to be demonstrated. Viremia was
accompanied by low peripheral blood T-lymphocyte counts and high
chemokine and cytokine levels in humans infected with H5N1 viruses
[6], suggesting that high viral load and the resulting acute
inflammatory responses have interconnected roles in influenza
H5N1 pathogenesis. Taken together, these findings highlight the
need for further studies to examine the relevance of viremia in H5N1
pathogenesis and virus transmission.
Table 1. Clinical observations in ferrets infected with H5N1
virus, A/VN/1203/04.
Day Postinfection
Group Clinical Sign 1 2 3 4 5 6 7 8 9 10 11
10 FLD50 Diarrhea 2
a 21 2 1 1
Discharge 5 7 9 7 7 3 2 1
Hypoactive 1 1
Recumbent 1 1
Found dead 2 1 3 1 1 1
1 FLD50 Diarrhea 1 1 1 2 2 1 1
Discharge 3 4 9 7 6 5 4 2 2
Hypoactive 3 4 1 1 1 1
Recumbent 1 1 1
Found dead 1 1 1 1
Note:
a)indicates number of surviving ferrets exhibiting clinical sign on the day
postinfection.
doi:10.1371/journal.pone.0012099.t001
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Virus
Avian H5N1 strain A/VN/1203/04 was obtained from the
Centers for Disease Control and Prevention (Atlanta, GA) (Lot
Number: E3/E2 1/18/07) and amplified in viable 10–11 day old
embryonated hen’s eggs (S&G Poultry, Clanton, AL). The virus
was maintained at 280uC until use in the study.
Determination of Viral titers
50 ml of allantoic fluid were harvested from euthanized hen’s eggs
and added to a microtiter plate. 50 ml of 0.5% turkey (tRBC) were
then added to all wells and plates were incubated for 30 minutes at
room temperature. Plates were read for agglutination or non-
agglutination. The 50% endpoint was determined by the method of
Reed and Muench
17 from virus dilutions testing positive for
hemagglutinin activity in Turkey Red Blood Cells (tRBC). Data
were expressed as 50% egg infectious dose (EID50) per milliliter.
Inoculation of ferrets
24 adult male ferrets (Triple F Farms, Sayre, PA) (The Southern
Research IACUC has approved the animal care and use proposal
(ACUP) #08-10-074B by IACUC Chairman, Larry Bowen) that
were 6,7 months of age and were seronegative for representative
currently circulating human influenza A strains prior to shipment
were used for the study. Ferrets were lightly anesthetized with a
solution of ketamine/xylazine/atropine formulated to provide
doses of 25 mg/kg ketamine, 1.7 mg/kg xylazine, and 0.05 mg/
kg of atropine to each animal. The animals were inoculated
intranasally with one ml of virus, approximately 500 ml to each
nare; 12 of ferrets with 1650% of ferret lethal dose (FLD50),
which equals to a concentration of 10610
8.5 (EID50/ml) viruses
and others with ten times of FLD50/ml viruses. Clinical signs of
infection, weight, and temperatures were recorded daily. Nasal
wash samples were collected from all ferrets on Days 0
(approximately 12 hours post-dose), 1, 2, 4, 6, and 8 for viral
load determination. A total of 0.5 ml from each animal were
collected and used to determine the viral load using the EID50
assay. Nasal washes were performed by slowly dripping 0.5 ml of
sterile solution of 1% v/v BSA, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 50 mg/ml gentamicin in Dulbecco’s Phosphate-
Buffered Saline into each nare, while allowing the animal to sneeze
and/or attempt to blow the solution out of the nostril into a sterile
Figure 1. Clinical signs of infection with H5N1 virus A/VN/1203/04 in ferrets. (A) Changes in body temperatures of infected ferrets. Ferrets
were inoculated with either 1 FLD50 or 10 FLD50 of the viruses, and body temperatures were monitored daily by the use of subcutaneous implantable
temperature transponders for 11 days postinfection. Each data point represents the mean value 6 SD for the surviving ferret(s). Note: only one
animal remained alive in the 10 FLD50 group (one value) on Day 9 postinfection. (B). Changes in weights of ferrets infected with the viruses. The
weights of ferrets were measured daily. The loss or gain of weight was calculated for each ferret as the percent change in the initial mean starting
weight on day 0. Values are the averages 6 SD for the ferret(s) alive for each group. (C) Virus titer in nasal wash with FLD50 assay. Nasal washes were
performed on Day 2, Day 4, and Day 6 postinfection in selection of ferrets in both groups using FLD50 assay.
doi:10.1371/journal.pone.0012099.g001
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and placed on dry ice immediately after collection. Samples were
stored at 280uC until used.
Tissue collection
A representative section of the left caudal lobe of the lung, nasal
turbinate, spleen, brain, and ileum tissue samples were collected
from each euthanized or deceased animal for viral load
determination. Samples were snapped frozen in liquid nitrogen
and stored at 280uC until analyzed for viral load determination.
On Days 0, 1, 2, 4, and 6 postinfection, blood samples were
collected from surviving ferrets, and stored at 280uC until used.
Titration of virus in nasal washes
Nasal washes were thawed and cleared by centrifugation. The
resulting supernatants were serially diluted (log10)i nD P B S
(Dulbecco’s Phosphate-Buffered Salines with antibiotics, 100 U/ml
Penicillin, l00 mg/ml Streptomycin and 50 mg/ml Gentamicin)
(Invitrogen, Carlsbad, CA). The 50% endpoint was determined by
the method of Reed and Muench [8] from egg dilutions testing
positive for hemagglutinin activity in tRBC. Virus titers were
expressed as EID50/ml. The limit of detection was 1610
0.5
EID50/100 ml since the initial sample dilution was 1:10.
Real-time PCR
Quantitative real-time RT-PCR was also used for detection of
virus load in the brain, lung, nasal turbinates, ileum, and blood.
Nucleic acids were isolated by using the QIAamp Viral RNA Mini
Kit (Valencia, CA 91355) according to the manufacturer’s
protocol. We designed a set of primers and probes for the matrix
gene, M, of the avian H5N1 influenza A virus, according to
GenBank database. The forward primer was 59-CGTCA-
GGCCCCCTCAAA-39, and the reverse primer was 59-
GGTGTTCTTTCCTGCAAAGA-39. The TaqMan probe was
oligonucleotide 59-TCAAGTTTCTGTGCGATCT-39, coupled
with a reporter dye [6-carboxy fluorescein] (FAM) at the 59 end, a
non-fluorescent quencher and a minor groove binder (MGB), that
served as a Tm enhancer, at the 39 end. The nucleic acids were
amplified and detected in an automated TaqMan 7500 Analyzer
by using QuantiTect
TM Probe RT-PCR kit (Qiagen Inc.,
Valencia, CA). The 25-ml PCR mixture consisted of 100 nM
primers and 100 nM probe. Following three thermal steps at 55uC
Table 2. Viral load using TaqMan RT-PCR in ferrets infected with virus, A/VN/1203/04 (fg, mean6SD).
Day Postinfection
Group Organ 4 5 6 7 8
Brain 8.51610
761.16610
8a 6.23610
7b 3.88610
765.27610
7 3.80610
764.30610
7
10 FLD50 Lung 2.95610
761.71610
6 2.06610
4b 1.10610
669.13610
5 8.51610
661.20610
5
N.T. 1.88610
462.20610
4 3.40610
462.28610
4
Ileum 4.44610
363.32610
3 4856337
Brain 3.94610
7b 7.76610
7b 3.11610
764.59610
6
1 FLD50 Lung 2.70610
3b 1.09610
5b 375862822
N.T. 9.33610
4b 5.50610
5b 813861094
Ileum 4.36610
3b 3.4761.08
Note:
a)Known concentrations of A/VN/1203/04 viral RNA (serially diluted: 10
8 to 10 fg) were used as templates and quantitative RT-PCR performed to generate a standard
curve. 25,30 mg of tissue from each organ was used for extraction of viral RNA and dissolved in 50 ml. 3 ml of the vRNA was used as template to perform real-time
PCR. Each value represents the average concentration of six reactions based on the standard curve.
b)indicates value for 1 animal.
doi:10.1371/journal.pone.0012099.t002
Table 3. Detection of viremia by TaqMan RT-PCR and cases of death of ferrets infected with H5N1 virus, A/VN/1203/04.
Group Animal code Viremia
a day postinfection Diarrhea day postinfection Died
b day postinfection
15 2 3 4
23 2 3 4
28 2 6
10 FLD50 17 6 7
32 6 4 7
33 6 6 7
34 6 8
1 FLD50 29 2 3 5
26 4 6
Note:
a)the day postinfection when virus was initially detected in the ferret blood sample.
b)the day postinfection when the animal was found dead.
doi:10.1371/journal.pone.0012099.t003
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two-step PCR at 95uC for 15 s and at 60uC for 1 min were
performed. The limit of detection was 1 fg of virus RNA per
reaction with the TaqMan assay since the initial sample dilution
was 1:10.
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